CL2021000343A1 - Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128) - Google Patents
Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)Info
- Publication number
- CL2021000343A1 CL2021000343A1 CL2021000343A CL2021000343A CL2021000343A1 CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1 CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1
- Authority
- CL
- Chile
- Prior art keywords
- interleukin
- peptide inhibitors
- divisional application
- receptor peptide
- receptor
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 que se pueden utilizar para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatorias.The present invention provides novel peptide inhibitors of the interleukin 23 receptor that can be used for the treatment or prevention of various diseases and disorders, including inflammatory bowel diseases.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000343A1 true CL2021000343A1 (en) | 2021-08-06 |
Family
ID=57757647
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000128A CL2018000128A1 (en) | 2015-07-15 | 2018-01-15 | Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases |
| CL2018003322A CL2018003322A1 (en) | 2015-07-15 | 2018-11-22 | Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128) |
| CL2021000343A CL2021000343A1 (en) | 2015-07-15 | 2021-02-09 | Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000128A CL2018000128A1 (en) | 2015-07-15 | 2018-01-15 | Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases |
| CL2018003322A CL2018003322A1 (en) | 2015-07-15 | 2018-11-22 | Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128) |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (en) |
| JP (1) | JP6858174B2 (en) |
| KR (1) | KR102513978B1 (en) |
| CN (1) | CN108348580B (en) |
| AU (1) | AU2016293619B2 (en) |
| BR (1) | BR112018000691A2 (en) |
| CA (1) | CA2991984A1 (en) |
| CL (3) | CL2018000128A1 (en) |
| CO (1) | CO2018000349A2 (en) |
| CR (1) | CR20180029A (en) |
| DO (1) | DOP2018000010A (en) |
| EA (1) | EA035733B9 (en) |
| EC (1) | ECSP18002929A (en) |
| HK (1) | HK1257747A1 (en) |
| IL (1) | IL256827A (en) |
| MX (1) | MX384213B (en) |
| NI (1) | NI201800008A (en) |
| PE (1) | PE20180571A1 (en) |
| PH (1) | PH12018500086A1 (en) |
| SG (1) | SG10201912066SA (en) |
| SV (1) | SV2018005614A (en) |
| UA (1) | UA123772C2 (en) |
| WO (1) | WO2017011820A2 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618003T3 (en) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9822157B2 (en) | 2013-03-15 | 2017-11-21 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| PT2986610T (en) | 2013-04-19 | 2018-03-09 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| PL3143037T3 (en) | 2014-05-16 | 2022-01-31 | Protagonist Therapeutics, Inc. | THIOETER PEPTIDES - ALPHA-4-BETA-7 INTEGRIN ANTAGONISTS |
| EP3169403B9 (en) | 2014-07-17 | 2024-07-03 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| KR102632018B1 (en) | 2015-02-20 | 2024-02-02 | 인사이트 홀딩스 코포레이션 | Bicyclic heterocycles as FGFR inhibitors |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| CA3049889A1 (en) | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| TW201920234A (en) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | Opioid agonist peptides and uses thereof |
| US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| BR112020022392A2 (en) | 2018-05-04 | 2021-02-02 | Incyte Corporation | solid forms of a fgfr inhibitor and processes for preparing them |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| JP7670605B2 (en) * | 2018-07-12 | 2025-04-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | Peptide inhibitors of the interleukin-23 receptor and their use for treating inflammatory diseases - Patents.com |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
| CN114269323B (en) * | 2019-07-01 | 2024-07-26 | 瓦利托尔有限公司 | Hydrophilic linkers for multivalent peptide conjugates |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3997105A4 (en) * | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| JP7720840B2 (en) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
| JP2023511551A (en) | 2020-01-15 | 2023-03-20 | ヤンセン バイオテツク，インコーポレーテツド | Peptide inhibitors of the interleukin 23 receptor and their use for treating inflammatory diseases |
| CN118027153A (en) * | 2020-01-15 | 2024-05-14 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20230357323A1 (en) * | 2020-06-29 | 2023-11-09 | University Of Washington | Human il23 receptor binding polypeptides |
| JP2023542867A (en) | 2020-09-11 | 2023-10-12 | グリンプス バイオ， インコーポレイテッド | In vitro protease activity detection for disease detection/diagnosis, staging, monitoring and treatment |
| MX2023005994A (en) * | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor. |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522188A (en) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Tricyclic Heterocycles as FGFR Inhibitors |
| KR20240034223A (en) * | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | Bicyclic peptide inhibitors of the interleukin-23 receptor |
| CN117999274A (en) * | 2021-07-14 | 2024-05-07 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor |
| CN118354781A (en) | 2021-12-01 | 2024-07-16 | 西兰制药公司 | Peptide inhibitors of interleukin-23 receptor |
| US20250223627A1 (en) * | 2022-03-09 | 2025-07-10 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
| IL317902A (en) | 2022-06-30 | 2025-02-01 | Sanofi Sa | New peptides as selective il-23 receptor antagonists |
| EP4622991A2 (en) * | 2022-11-21 | 2025-10-01 | Janssen Pharmaceutica NV | Synthesis of a cyclic peptide |
| WO2024155547A2 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| IL322423A (en) | 2023-01-31 | 2025-09-01 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
| WO2024227437A1 (en) * | 2023-05-04 | 2024-11-07 | 西藏海思科制药有限公司 | Preparation of peptide inhibitor of interleukin-23 receptor and use thereof |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2025051920A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2025051912A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| BRPI0807728A2 (en) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | glucagon / glp-1 receptor co-agonists |
| JP2011501941A (en) * | 2007-07-06 | 2011-01-20 | バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ | IL-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) * | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| EP3065757A4 (en) * | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| EP3169403B9 (en) * | 2014-07-17 | 2024-07-03 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active Active
- 2016-07-15 MX MX2018000542A patent/MX384213B/en unknown
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en not_active Withdrawn
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en not_active Application Discontinuation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en not_active IP Right Cessation
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000343A1 (en) | Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128) | |
| MX2023004593A (en) | Tyk2 inhibitors and uses thereof. | |
| CY1122467T1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| CL2018001367A1 (en) | Compositions comprising bacterial strains | |
| CL2018001349A1 (en) | Compositions comprising bacterial strains | |
| CO2017013446A2 (en) | Compositions comprising bacterial strains of the genus Bacteroides | |
| CL2018001368A1 (en) | Compositions comprising bacterial strains | |
| CL2017003142A1 (en) | Compositions comprising bacterial strains | |
| ECSP19015192A (en) | COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | |
| BR112019012062A2 (en) | treating a gastrointestinal tract disease with a jak inhibitor and devices | |
| MX2018006240A (en) | COMPOSITIONS THAT INCLUDE BACTERIAL VINS. | |
| EA201691134A1 (en) | NEW GLUTAMINASE INHIBITORS | |
| MX389449B (en) | COMPOSITIONS OF C1-INH AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY. | |
| CR20190394A (en) | AUTOTAXIN INHIBITOR COMPOUNDS(Divisional de Exp. 2016-0289) | |
| EA201792604A1 (en) | AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS | |
| PL410665A1 (en) | Arginase inhibitors and their therapeutical applications | |
| JOP20190129B1 (en) | Compositions and methods for adjuvants for 5-HT1F from pyridinoylpiperidine | |
| MX380290B (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS. | |
| MX374654B (en) | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T. | |
| EA201791937A1 (en) | ANTI-INFLAMMATORY POLYPEPTIDES | |
| CL2016002321A1 (en) | Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders. | |
| EA202091524A1 (en) | INHIBITORS OF THE PROTEASE 2 ACTIVATED RECEPTOR | |
| MA40642A (en) | Novel peptide derivatives and uses thereof | |
| AR106769A1 (en) | COMPOSITIONS THAT INCLUDE BACTERIAL VINTAGES | |
| EA202090846A1 (en) | NEW GLUTAMINASE INHIBITORS |